Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR

Joint Bone Spine

Volumn 82, Issue 1, 2015, Pages 13-17

  Combe, Bernard ^a   Rincheval, Nathalie ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Biomarkers; Cohort; Diagnosis; Early arthritis; Pathophysiology; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; METHOTREXATE;

COHORT ANALYSIS; CORTICOSTEROID THERAPY; DAS28; DISEASE COURSE; ECHOGRAPHY; ENVIRONMENTAL EXPOSURE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HEREDITY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; ARTHRITIS; ARTHRITIS, RHEUMATOID; BLOOD; FACTUAL DATABASE; FRANCE; PATHOPHYSIOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ARTHRITIS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; DATABASES, FACTUAL; DISEASE PROGRESSION; FRANCE; HUMANS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84922120579     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.07.003     Document Type: Short Survey

References (56)

1. Combe B., Benessiano J., Berenbaum F., et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France. Methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007, 74:440-445. [Epub 2007 Jul 26].
2. Aletaha D., Neogi T., Silman A.J., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588. [Arthritis Rheum 2010;62:2582-91].
3. Combe B., Rincheval N., Benessiano J., et al. Five-year favourable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol 2013, 40:1650-1657. 10.3899/jrheum.121515.
4. Combe B. The French early arthritis register. Clin Exp Rheumatol 2003, 21:S123-S128.
5. Salliot C., Dawidowicz K., Lukas C., et al. PTPN22 R620W genotype-phenotype correlation analysis and gene-environment interaction study in early rheumatoid arthritis: results from the ESPOIR cohort. Rheumatology (Oxford) 2011, 50:1802-1808.
6. Vesperini V., Lukas C., Fautrel B., et al. Does cigarette smoking influence activity and severity in early rheumatoid arthritis? Results from the ESPOIR cohort. Arthritis Care Res (Hoboken) 2013, 65:1899-1906. 10.1002/acr.22057.
7. Salliot C., Bombardier C., Saraux A., et al. Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort. Ann Rheum Dis 2010, 69:1683-1686.
8. Mouterde G., Lukas C., Logeart I., et al. Predictors of radiographic progression in the ESPOIR cohort. The season of first symptoms may influence the short-term outcome in early arthritis. Ann Rheum Dis 2011, 70:1251-1256.
9. Ruyssen-Witrand A., Lukas C., Nigon D., et al. Association of IL-2RA and IL-2RB genes with erosive status in early rheumatoid arthritis patients (ESPOIR and RMP cohorts). Joint Bone Spine 2013, 10.1016/j.jbspin.2013.10.002.
10. Gazal S1, Sacre K., Allanore Y., et al. Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. Ann Rheum Dis 2014, 10.1136/annrheumdis-2013-204581.
11. Fautrel B., Combe B., Rincheval N., et al. Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data. Ann Rheum Dis 2011, 71:386-389.
12. Saraux A., Tobon G.J., Benhamou M., et al. Potential classification criteria for rheumatoid arthritis after two years: results from a French multicenter cohort. Arthritis Care Res 2013, 65:1227-1234. 10.1002/acr.21982.
13. Knevel R., Lukas C., van der Heijde D., et al. Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data-driven phase. Ann Rheum Dis 2013, 72:590-595.
14. van der Heijde D., van der Helm-van Mil H.M.A, Aletaha D., et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013, 72:479-481.
15. Zhang B., Combe B., Rincheval N., et al. Validation of ACR/EULAR Definition of Remission in Rheumatoid Arthritis from RA Practice: the ESPOIR cohort. Arthritis Res Ther 2012, 14:R156.
16. Hmamouchi I., Combe B., Le Loet X., et al. Prevalence, concordance and predictors of early and sustained remission assessed by various validated indices in the early arthritis "ESPOIR" cohort. Joint Bone Spine 2014, (pii: S1297-319X(14)00051-7, doi: 10.1016).
17. Castrejon I., Pincus T., Guillemin F., et al. Possible remission criteria in rheumatoid arthritis without a formal joint count, based on careful joint examination and self-report RAPID3 score: data from the ESPOIR usual care cohort. J Rheumatol 2013, 40:386-393. 10.3899/jrheum.121059.
18. Fautrel B., Granger B., Combe B., et al. Risk model of rapid radiographic progression in early rheumatoid arthritis treated by methotrexate in the ESPOIR cohort. Arthritis Res Ther 2012, 19:R249.
19. Tobon G., Saraux A., Lukas C., et al. First-year radiographic progression is the best predictor of further progression in early arthritis: results of a large national French cohort. Arthritis Care Res 2013, 10.1002/acr.22078.
20. Boyer J.F., Bongard V., Cantagrel A., et al. Link between traditional cardiovascular risk factors and inflammation in early arthritis patients. Arthritis Care Res (Hoboken) 2012, 64:872-880.
21. Dadoun S., Guillemin F., Lucier S., et al. Work productivity loss in early arthritis during the first 3 years of disease. A study from the ESPOIR cohort. Arthritis Care Res (Hoboken) 2014, 10.1002/acr.22298.
22. Combe B., Logeart I., Belkacemi M., et al. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis 2014.
23. Castrejon I., Pincus T., Soubrier M., et al. GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. Rheumatology (Oxford) 2013, 52:1890-1897. 10.1093/rheumatology/ket230.
24. Rat A.C., Pouchot J., Fautrel B., et al. Factors associated with fatigue in early arthritis: Results from the ESPOIR cohort. Arthritis Care Res (Hoboken) 2012, 10.1002/acr.21647.
25. Bacconnier L., Rincheval N., Flipo R.M., et al. Depression and anxiety risk in early rheumatoid arthritis: results from the ESPOIR cohort. EULAR congress 2011.
26. Gaujoux-Viala C., Rat A.C., Guillemin F., et al. Comparison of the EQ-5D and the short form 6D utility measures in French patients with early arthritis: Results from the ESPOIR cohort. J Rheumatol 2011, 38:1576-1584.
27. Gaujoux-Viala C., Rat A.C., Guillemin F., et al. Responsiveness of the EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Annals Rheum Dis 2012, 71:1478-1483.
28. Gaujoux-Viala C., Fautrel B., Guillemin F., et al. Who are the patients with early arthritis with worse than death scores on the EQ-5D? Results from the ESPOIR cohort. Rheumatology (Oxford) 2013, 52:832-838. 10.1093/rheumatology/kes270.
29. Devauchelle V., Josseaume T., Samjee I., et al. Ability of oblique foot radiographs to detect erosions in early arthritis: Results in the ESPOIR cohort. Arthritis Rheum 2008, 59:1729-1734.
30. Cyteval C., Miquel A., Hoa D., et al. Rheumatoid arthritis of the hand: monitoring with a simplified MR imaging scoring method-preliminary assessment. Radiology 2010, 256:863-869.
31. Funck-Brentano T., Etchepare F., Joulin S.J., et al. Benefits of ultrasonography in the management of early arthritis: a cross-sectional study of baseline data from the ESPOIR cohort. Rheumatology (Oxford) 2009, 48:1515-1519.
32. Millot F., Clavel G., Etchepare F., et al. Musculoskeletal ultrasonography in healthy subjects and ultrasound criteria for early arthritis (The ESPOIR Cohort). J Rheumatol 2011, 38:613-620.
33. Funck-Brentano T., Grandjbakhch F., Etchepare F., et al. Sonographic erosions and power-doppler signal predict radiographic damage in early arthritis: The ESPOIR ultrasonography longitudinal study. Arthritis Care Res 2012, 10.1002/acr.21912.
34. Gossec L., Combescure C., Rincheval N., et al. Relative clinical influence of clinical, laboratory, and radiological investigations in early arthritis on the diagnosis of rheumatoid arthritis. Data from the French early arthritis cohort ESPOIR. J Rheumatol 2010, 37:2486-2492.
35. Guennoc X., Narbonne V., Jousse-Joulin S., et al. Is Screening for hepatitis B and C useful in patients with recent-onset polyarthritis? Results of the ESPOIR cohort study. J Rheumatol 2009, 36:1407-1413.
36. Le Boëdec M., Marhadour T., Devauchelle-Pensec V., et al. Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: study of three cohorts (ESPOIR, VErA, and Brittany). Semin Arthritis Rheum 2013, 42:474-481. 10.1016/j.semarthrit.2012.08.001.
37. Varache S., Narbonne V., Jousse-Joulin S., et al. Is routine viral screening useful in patients with recent-onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study. Arthritis Care Res (Hoboken) 2011, 63:1565-1570. 10.1002/acr.20576.
38. Nicaise-Roland P., Nogueira L., Demattei C., et al. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Ann Rheum Dis 2013, 72:357-362.
39. Gossec L., Paternotte S., Combe B., et al. Repeated anti-citrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis. Results from the ESPOIR cohort. J Rheumatol 2014, 41:41-46. 10.3899/jrheum.121313.
40. Cornillet M., Ruyssen-Witrand A., Constantin A., et al. 1.60 Autoantibodies to human citrullinated fibrinogen (AhFibA) and their subfamilies directed to the fibrin peptides α36-50Cit38,42 and β60-7460,72,74 are prognostic markers of radiographic damage in the very early arthritides of the French ESPOIR cohort. Ann Rheum Dis 2014, 73:A26. 10.1136/annrheumdis-2013-205124.59.
41. Gottenberg J.E., Miceli-Richard C., Ducot, et al. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009, 11:R114.
42. Gottenberg J.E., Dayer J.M., Lukas C., et al. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 2012, 71:1243-1248.
43. Meyer M., Sellam J., Fellahi S., et al. Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther 2013, 15:R210.
44. Mouterde G., Lukas C., Flipo R.M., et al. ACPA, rheumatoid factor and differences in clinical presentation of early arthritis: results from the ESPOIR Cohort. J Rheumatol 2014, 10.3899/jrheum.130884.
45. Gaujoux-Viala C., Paternotte S., Combe B., et al. Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its sub-optimal use: results from the ESPOIR early synovitis cohort. Rheumatology (Oxford) 2012, 51:1648-1654.
46. Lukas C., Guillemin F., Landewé R., et al. Factors determining a DMARD initiation in early arthritis patients. The ESPOIR cohort study. Clin Exp Rheumatol 2009, 27:84-91.
47. Benhamou M., Rincheval N., Roy C., et al. The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR Cohort. J Rheumatol 2009, 36:5. 10.3899/jrheum.080762.
48. Fautrel B., Benhamou M., Foltz V., et al. Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. Rheumatology (Oxford) 2010, 49:147-155.
49. Lukas C., Combe B., Ravaud Ph, et al. Very early DMARD initiation in inflammatory arthritis is effective in inhibition of radiographic progression. Arthritis Rheum 2011, 63:1804-1811. 10.1002/art.30371.
50. Soubrier M., Lukas C., Sibilia J., et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011, 70:611-615.
51. Escalas C., Dalichampt M., Combe B., et al. Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort. Ann Rheum Dis 2012, 71:1803-1808.
52. Sellam J., Kotti S., Fellahi S., et al. Serum hepcidin level is not an independent surrogate biomarker of disease activity or of radiographic progression in rheumatoid arthritis: results from ESPOIR cohort. Ann Rheum Dis 2013, 72:312-314.
53. Ruyssen-Witrand A., Guernec G., Nigon D., et al. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. Ann Rheum Dis 2014, 10.1136/annrheumdis-2013-204906.
54. Chevreul K., Haour G., Lucier S., et al. Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation - an economic analysis based on the ESPOIR cohort. PLoS One 2014, 9:e97077. [eCollection 2014]. 10.1371/journal.pone.0097077.
55. Gaujoux-Viala C., Gossec L., Cantagrel A., et al. Recommendations of the French Society of Rheumatology for the management of rheumatoid arthritis. Joint Bone Spine 2014, 10.1016/j.jbspin.2014.05.002.
56. Smolen J.S., Landewé R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509. 10.1136/annrheumdis-2013-204573.